Sulfuretin inhibits the inflammatory responses by suppressing the NF-κB pathway in type 1 diabetes models. Sulfuretin (40 μg/kg; single intraperitoneal injection 2 h after the last OVA challenge) suppresses ovalbumin (OVA)-induced chemotaxis and airway inflammation.